The potential of real-time analytics to improve care for mechanically ventilated patients in the intensive care unit by Bakker, L.J. (Lytske) et al.
Bakker et al. Cost Eff Resour Alloc           (2020) 18:57  
https://doi.org/10.1186/s12962-020-00254-4
RESEARCH
The potential of real-time analytics 
to improve care for mechanically ventilated 
patients in the intensive care unit: an early 
economic evaluation
Lytske Bakker1,2* , Katerina Vaporidi3, Jos Aarts1 and William Redekop1,2
Abstract 
Background: Mechanical ventilation services are an important driver of the high costs of intensive care. An opti-
mal interaction between a patient and a ventilator is therefore paramount. Suboptimal interaction is present when 
patients repeatedly demand, but do not receive, breathing support from a mechanical ventilator (> 30 times in 3 min), 
also known as an ineffective effort event (IEEV). IEEVs are associated with increased hospital mortality prolonged 
intensive care stay, and prolonged time on ventilation and thus development of real-time analytics that identify IEEVs 
is essential. To assist decision-making about further development we estimate the potential cost-effectiveness of real-
time analytics that identify ineffective effort events.
Methods: We developed a cost-effectiveness model combining a decision tree and Markov model for long-term 
outcomes with data on current care from a Greek hospital and literature. A lifetime horizon and a healthcare payer 
perspective were used. Uncertainty about the results was assessed using sensitivity and scenario analyses to examine 
the impact of varying parameters like the intensive care costs per day and the effectiveness of treatment of IEEVs.
Results: Use of the analytics could lead to reduced mortality (3% absolute reduction), increased quality adjusted life 
years (0.21 per patient) and cost-savings (€264 per patient) compared to current care. Moreover, cost-savings for hos-
pitals and health improvements can be incurred even if the treatment’s effectiveness is reduced from 30 to 10%. The 
estimated savings increase to €1,155 per patient in countries where costs of an intensive care day are high (e.g. the 
Netherlands). There is considerable headroom for development and the analytics generate savings when the price 
of the analytics per bed per year is below €7,307. Furthermore, even when the treatment’s effectiveness is 10%, the 
probability that the analytics are cost-effective exceeds 90%.
Conclusions: Implementing real-time analytics to identify ineffective effort events can lead to health and financial 
benefits. Therefore, it will be worthwhile to continue assessment of the effectiveness of the analytics in clinical prac-
tice and validate our findings. Eventually, their adoption in settings where costs of an intensive care day are high and 
ineffective efforts are frequent could yield a high return on investment.
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Background
Annual intensive care costs in the United States repre-
sent more than 13% of all hospital costs [1]. The costs 
of an intensive care unit (ICU) day per patient are high 
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(i.e. €5,695) and an important factor that contributes to 
these high daily costs is whether or not patients receive 
mechanical ventilation [2]. Therefore, better management 
of mechanically ventilated patients could be a worthwhile 
investment when it reduces length of stay and their time 
on ventilation support.
One way to achieve better outcomes in the intensive 
care is by using analytics to process the huge amounts of 
monitoring data that are continuously collected in order 
to improve clinical decision-making [3]. Ventilation mon-
itors in the ICU generate a wealth of data on a patient’s 
status and patient-monitor interaction. Ideally, this data 
can be used to help clinicians intervene promptly when 
the interaction between the patient and the monitor is 
poor. One example of poor interaction is when a patient 
tries but does not receive a breath. These so-called ‘inef-
fective efforts’ are reflected in the airway pressure and 
airflow data from the monitor [4]. When many ineffective 
efforts occur in a short period of time  (> 30 ineffective 
efforts in 3 min.) it is referred to as an ineffective effort 
event (IEEV) which have been associated with higher 
hospital mortality, an increase in ICU length of stay of 
almost 10 days and prolonged time on mechanical venti-
lation [5]. Timely identification of ineffective effort events 
is crucial and early-warning systems using big data ana-
lytics have been portrayed as an important means to 
improve care for mechanically ventilated patients [4, 6] 
since the complexity and velocity required to process this 
data in real-time are beyond the capacities of humans 
such as healthcare professionals.
Real-time analytics of ventilation data would enable 
clinicians to identify IEEVs and intervene accordingly 
thereby shortening their duration and potentially reduc-
ing mortality risks and healthcare costs. Several types of 
interventions are recommended to improve the interac-
tion between a patient and a mechanical ventilator such 
as, adjustment of ventilator settings, reducing sedation 
when managing pain and anxiety [7, 8] and adjustments 
in the management of bronchodilation [8]. Develop-
ing real-time analytics that identify IEEVs would enable 
clinicians to adopt these interventions currently already 
recommended when other forms of suboptimal interac-
tion are present, identified manually for instance through 
waveform graphics [9]. However, large investments will 
need to be made in further research and development 
before these analytics could be implemented in clini-
cal practice; the need for these investments can pose a 
major barrier for their development and future success. 
We aim to assist future development and clinical trial 
plans by identifying the performance requirements of the 
technology such as maximum costs or minimum efficacy. 
We performed a cost-effectiveness analysis in which we 
estimated how analytics that identify IEEVs in real-time 
could generate health improvements and/or financial 
savings.
Methods
We used a decision tree model to assess the potential 
cost-effectiveness of analytics to detect IEEVs. Short 
term effects were estimated, such as hospital mortality 
and length of stay, but also long-term outcomes such as 
life years gained and quality adjusted life years gained 
(QALYs). Where policy makers involved with national 
reimbursement decisions would be familiar with out-
comes such as life years gained and QALYs developers 
of analytics and hospitals deciding on their acquisition 
may be less familiar with these outcomes but interested 
in mortality and length of stay. The target population 
consisted of patients who receive assisted modes of ven-
tilation in a Greek ICU. In current care, IEEVs are not 
detected in these patients, which means that clinicians do 
not intervene to stop them. We compared current care 
with the intervention in which IEEVs are detected with 
analytics that process data from mechanical ventilators in 
real-time. Their detection would enable clinicians to pro-
vide treatment to reduce duration of the IEEV.
Decision tree model
We developed a decision tree model that compared the 
health and cost outcomes of current care to the use of 
analytics for early detection of IEEVs (Fig. 1). In the inter-
vention arm, data from ventilation monitors is analyzed 
in real-time and an alarm is generated when a patient has 
an IEEV (branch 1–5). An alarm sounds when patients 
are labelled as having IEEVs (branch 1, 2 and 3) while 
no alarm sounds when patients are labelled as not hav-
ing IEEVs (branch 4 and 5). When the alarm sounds, a 
clinician will carry out a treatment that may or may not 
be successful (branch 1 vs branch 2). The other arm in 
the decision tree represents current care (branch 6). 
Since IEEVs are currently not identified, no treatment is 
performed.
Figure  1 also shows a Markov model with four states 
(‘ICU’, ‘hospital ward’, ‘discharged’ and ‘death’), which was 
used to estimate the long-term outcomes of IEEV detec-
tion and treatment. At the start of this model, all patients 
start in the ICU. At the end of the first cycle, patients 
transition to the general ‘hospital ward’ or ‘death’; the 
cycle length equals the median length of ICU stay. 
Within the data used to model results, no patients were 
readmitted to the ICU after ICU discharge. Therefore, 
we excluded the possibility to transition back to the ICU 
from the hospital ward.
At the end of the second cycle, all patients in the ‘hos-
pital ward’ transition to either ‘discharged’ or ‘death’; 
this cycle’s length equals the median length of hospital 
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stay (following ICU discharge). For the remainder of the 
cycles, patients can remain in the ‘discharged’ state or die; 
the length of these cycles was one year. Because it was 
uncertain as to where in the cycle patients transitioned, 
a half-cycle correction was applied assuming patients 
transitioned on average in the middle of the cycle. With-
out the correction, patients would either be assumed to 
transition at the start or end of a cycle incurring more 
or less of the costs they should be assigned. The time 
horizon was lifetime and we adopted a healthcare payer 
perspective including only direct medical costs. Since 
Greece does not have a national guideline for performing 
economic evaluations, health outcomes and costs were 
discounted at a rate of 3.5%. Key model assumptions can 
be found in Additional file 1: Table S1 and the model was 
built in R v.3.3.1.
Analytics and treatment parameters
Table  1 shows the values and distributions of the 
input parameters used in the model. Identifying IEEVs 
and the subsequent treatment can be complex and to 
estimate its potential several parameters need to be 
combined. First, ineffective efforts need to be iden-
tified from airway pressure and airflow data. In the 
Greek ICU a prototype monitor was used to identify 
ineffective efforts. Data from this ‘ineffective effort 
monitor’ can be used to calculate ineffective effort 
events. The sensitivity and specificity of the algorithm 
that identified ineffective efforts were derived from the 
literature [10]. Real-time analytics would use the data 
from the prototype monitor to identify clusters of inef-
fective effort events [5]. The prior probability of IEEVs 
was 38% [5]. When an IEEV is detected, the clinician 
can perform one of the following treatments; adjust 
the ventilator settings, reduce sedation when managing 
pain and anxiety [7, 8], or change the management of 
secretions and bronchodilation [8].
There is evidence that patients experiencing inef-
fective effort events have worse outcomes such as 
increased hospital mortality and prolonged ICU stay 
[5]. However, assessing the probability that treatments 
are effective when IEEVs occur can only be done once 
these real-time analytics are available. Therefore, we 
assessed the impact on health and cost benefits when 
varying the probability of effective treatment from 0 
to 50%. Because the treatment was performed shortly 
after an IEEV occurred (3 min) while the median dura-
tion of the events was 21  min [5] we assumed that an 
effective treatment would lead to an outcome similar to 
those without IEEVs.
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Fig. 1 Cost-effectiveness model structure comparing use of real-time analytics to current care. All probabilities were estimated using the sensitivity, 
specificity and prior probability of having an IEEV reported in this table. ICU Intensive Care Unit, IEEV Ineffective Effort Event, FN False Negative, TP 
true positive, FP false positive, TN true negative, M Markov Model
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Health parameters
Long term health benefits were quantified in life years 
gained and QALYs gained. QALYs are estimated by mul-
tiplying the life years gained by the quality of life in those 
years. Therefore, if a patient lives two extra years but in 
suboptimal health, the QALYs gained will be less than 
two.
We used patient data on current care from a medical-
surgical ICU in Greece (the University hospital of Her-
aklion (PAGNI)) [5] to estimate life years gained and 
QALYs. The study was approved by the hospital’s ethics 
committee and detailed results from the observational 
study can be found elsewhere [5]. All 110 patients in that 
study received assisted modes of mechanical ventilation 
for > 12 h (total of 4,456,537 breaths).
Life years gained were estimated by combining patient 
level data with results from the literature. The prob-
ability of surviving the ICU was considerably higher—
although not statistically significant- amongst patients 
without IEEVs compared to patients with IEEVs (75% vs 
63% (p = 0.249)). The probability of surviving the hos-
pital was statistically significantly higher for patients 
without IEEVs compared to patients with IEEVs (67% vs 
41% (p = 0.025). Life years gained after discharge were 
Table 1 Input parameters for the cost-effectiveness model
IEEVs ineffective effort events, ICU intensive care unit, LOS length of stay, MV mechanical ventilation, Hospital data Patient level data from the intensive care unit of 
PAGNI in Greece




Highest estimate Distribution Source
Discount rate costs (%) 3.5 3 5 –
Discount rate health benefits (%) 3.5 1 5 –
Sensitivity prototype monitor (%) 88 79 94 Beta [10]
Specificity prototype monitor (%) 99 80 100 Beta pert [10]
Prior probability of IEEVs (%) 38 10 50 Beta pert [5]
Treatment’s effectiveness (%) 30 0 50 – [Expert opinion]
ICU survival (%)
 With IEEVs 63 48 77 Beta Hospital data
 Without IEEVs 75 63 84 Beta Hospital data
Hospital survival (%)
 With IEEVs 41 27 57 Beta Hospital data
 Without IEEVs 67 55 77 Beta Hospital data
Hazard ratio of death after ICU admission vs no. admission 2.01 1.64 2.46 Normal [11]
Quality of Life (utilities)
 ICU 0.297 0.24 0.36 Beta Assumed
 Hospital 0.6 0.53 0.67 Beta [14]
 Year 1 post discharge 0.67 0.62 0.71 Beta [15]
 Year 2–10 post discharge 0.70 0.65 0.75 Beta [15]
 Year > 10 post discharge 0.68 0.62 0.74 Beta [15]
Resource Use
ICU LOS (days)
 With IEEVs 28 23 34 Gamma Hospital data
 Without IEEVs 22 18 27 Gamma Hospital data
Time on MV (days)
 With IEEVs 21 17 27 Gamma Hospital data
 Without IEEVs 15 12 17 Gamma Hospital data
Hospital LOS post-ICU discharge (days) 17.3 14 21 Gamma [20]
Unit costs (in 2019 Euros)
Analytics licensing (per bed, per year) 1918 100 20,000 – [16]
Treatment 100 57 155 Gamma [Expert opinion]
ICU day 686 392 1060 Gamma [17]
Hospital day 298 170 460 Gamma [18]
Reduction in ICU costs when patients no longer receive MV (%) 10 0 35 Beta pert [Expert opinion]
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estimated using the post-discharge hazard ratio of mor-
tality for ICU patients [11] combined with a baseline haz-
ard of the Greek general population [12, 13].
Unsurprisingly, no research is available on quality of 
life of patients during ICU stay. Therefore, using a value 
set from the United Kingdom, quality of life for those in 
the ICU whilst on mechanical ventilation was assumed 
to be 0.297. This corresponds with an EQ-5D state of 
individuals who have extreme problems with mobility 
and self-care, cannot perform their usual activities but 
no pain, discomfort or anxiety. QALYs during a hospital 
stay were estimated using utility estimates derived from 
the literature [14]. Quality of life after discharge was esti-
mated using the mean age of the patients and the time 
since ICU discharge [15].
Resource use and unit costs
To estimate costs, we obtained time on mechanical venti-
lation and length of stay from the patient level data from 
PAGNI. For patients with IEEVs, median ICU length of 
stay was longer than for patients without IEEVs (26 vs 
17 days (p = 0.017)), as was the median time on mechani-
cal ventilation (16 vs 11  days (p = 0.02)). We assumed 
annual licensing costs for the analytics (€1,918) to esti-
mate the costs of the analytics per ICU day [16]. This 
estimate was varied extensively in uncertainty analyses. 
The costs included for treatment when IEEVs occur were 
assumed to be low since the interventions currently per-
formed to improve interaction between a patient and 
the mechanical ventilator are easy and cheap to per-
form (i.e. adjusting sedation, adjustment of ventilator 
settings). Base case estimates for the costs per ICU day 
[17] and costs per hospital day [18] were derived from 
micro-costing studies conducted in Greece. There was a 
considerable amount of uncertainty in especially the ICU 
costs per day and these were therefore varied extensively 
in the univariate uncertainty analyses. These daily ICU 
costs were decreased by 10% for patients who remained 
in the ICU but were successfully weaned. All costs were 
adjusted to 2019 euros.
Cost‑effectiveness analysis
We determined the incremental costs, life years gained, 
quality adjusted life years and the incremental cost-
effectiveness ratio of using analytics to identify IEEVs 
compared to current care. First, base-case estimates for 
all outcomes were calculated using the most likely input 
values based on patient-level data and the literature. We 
then performed univariate sensitivity analyses in which 
one input parameter at a time was varied to determine 
how they affected the cost-effectiveness results. Costs 
of an ICU day are much higher in countries such as the 
Netherlands compared to the parameter values used in 
the base case [19]. Therefore, we assessed the impact of 
increasing this value to the Dutch estimate (€2153) on 
the cost-effectiveness results. Finally, we also examined 
a ‘worst case’ scenario and ‘best case’ scenario using the 
highest and lowest estimates presented in Table 1. In the 
‘worst case’ scenario the analytics and the treatment were 
expensive, whilst the number of people with IEEVs, the 
probability of effective treatment, and the sensitivity and 
specificity of the ineffective effort algorithm were all low. 
For the ‘best case’ scenario, the analytics and interven-
tion costs were reduced whilst the probability of having 
IEEVs, the probability of an effective treatment, sensitiv-
ity and specificity were all high.
Probabilistic sensitivity analysis and headroom analysis
In a probabilistic sensitivity analysis (PSA) we varied 
all parameters simultaneously with the exception of the 
price and the probability of the treatment’s effective-
ness. In the PSA we performed 10,000 simulations during 
which random parameter values for all input parameters 
were simultaneously drawn from their underlying dis-
tributions. We ran the PSA three times using different 
levels for the probability that the treatment is effective 
(10%, 30% and 50%). The results were shown using cost-
acceptability curves, which display the probability that 
using the analytics is cost-effective given various willing-
ness-to-pay thresholds. We also estimated the headroom 
per patient which is the maximum price that could be 
charged for the analytics per patient or per bed given a 
fixed willingness-to-pay and can be estimated as follows;
where N are the savings given a price of zero for the ana-
lytics per bed, λ is the threshold used and Q refers to the 
incremental QALYs gained [21]. We assumed the device 
would be sold to a hospital on a per bed basis and that 
patients needed the device for an average of 17  days. 
Since no official willingness-to-pay threshold is used in 
Greece, we adopted three alternative thresholds. The first 
two were based on opportunity costs proposed by Woods 
et  al. resulting in thresholds of €4,946 and €7758 [22]. 
Alternatively we also used a threshold of €30,000 which 




We found that the analytics could reduce hospital mor-
tality (3% absolute reduction), increase QALYs (0.21 
per person) and lead to cost-savings (€246 per person) 
when the probability of the treatment’s effectiveness 
is 30% (Table 2). Even if the probability that the treat-
ment is effective is small (10%) health improvements 
Headroom = N +  ∗ Q
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and cost-savings were gained. Long-term health out-
comes (QALYs and life years) were influenced by hos-
pital survival and the discount rate of health benefits. 
Incremental costs were greatly influenced by the costs 
of the analytics, the prevalence of IEEVs, the probabil-
ity the treatment is effective, and the costs of an ICU 
day (Fig. 2). Increasing sensitivity and specificity of the 
monitor that identifies ineffective efforts had a limited 
effect on costs; but when sensitivity increased so did 
health gains. In the base-case scenario, when the price 
of the analytics was €1918, cost-savings were gener-
ated (Fig. 3). When the costs of the analytics exceeded 
€7307 per year, using the analytics was more expensive 
than current care. Moreover, when costs of an ICU day 
were high (i.e. €2153), savings increased from €183 to 
€1155 per patient. In the ‘best case’ scenario, the ana-
lytics resulted in greater health benefits (0.50 QALYs), 
reduced mortality (6% absolute reduction) and higher 
cost-savings than the base case scenario (€831). How-
ever, in the ‘worst case’ scenario, using the analytics 
offered no health benefits and increased average costs 
per patient (€895).
Probabilistic sensitivity analysis and headroom analysis
Figure 4 shows a cost-effectiveness plane that illustrates 
the degree of uncertainty surrounding the differences in 
costs and effectiveness between using real-time analytics 
and current care. Three scatterplots are shown, one for 
each of the scenarios. This figure shows us that a greater 
probability that the treatment is effective increases the 
degree of cost-savings and health gain from using real-
time analytics. The cost-effectiveness acceptability curves 
shown in Fig. 5 present the probability that the analytics 
are considered cost-effective for a range of willingness-
to-pay thresholds. We presented three different accept-
ability curves each with their own probability of the 
treatment’s effectiveness. Figure  5 illustrates that for a 
low willingness-to-pay threshold (€4946), the probability 
that the analytics for IEEVs are cost-effective exceeds 90% 
even when the probability that the treatment is effective 
is 10%. The headroom was €1963 per patient (equivalent 
to €41,468 per bed), for a willingness-to-pay threshold 
of €7758. Moreover, for a threshold of €30,000 the head-
room per patient was much higher (€6634 per patient 
equivalent to €140,128 per bed). 
Table 2 Discounted results from the base case analysis and the worst and best case scenarios
ICER Incremental Cost Effectiveness Ratio, QALYs Quality Adjusted Life Years, ICU intensive care unit
a High costs of the analytics (€20,000) and treatment intervention(€155), Low probability of IEEVs (0.1), sensitivity(0.79), specificity (0.8) and an unsuccessful treatment 
intervention (0)
b Low costs of the analytics (€100) and the intervention (€57), High probability of IEEVs (0.5), sensitivity(94%), specificity (1) and probability of successful intervention 
(0.5)
c High costs of an ICU day
Scenario Costs € Length of ICU stay Hospital Mortality Life Years QALYs
Base case
 Current care 19,501 24.28 0.43 6.87 4.72
 With analytics 19,255 23.68 0.40 7.18 4.93
 Incremental − 264 − 0.6 − 0.03 0.31 0.21
 ICER Dominant Dominant Dominant Dominant
Worst  casea
 Current care 18,474 22.6 0.36 7.73 5.31
 With analytics 19,369 22.6 0.36 7.73 5.31
 Incremental 895 0 0 0 0
 ICER – – – –
Best  caseb
 Current care 19,942 25.00 0.46 6.50 4.46
 With analytics 19,111 23.59 0.40 7.22 4.96
 Incremental − 831 − 1.41 − 0.06 0.72 0.50
 ICER Dominant Dominant Dominant Dominant
High ICU day  costsc
 Current care 53,520 24.28 0.43 6.87 4.72
 With analytics 52,366 23.68 0.40 7.18 4.93
 Incremental − 1155 − 0.6 − 0.03 0.31 0.21
 ICER Dominant Dominant Dominant Dominant
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Fig. 2 Tornado diagram illustrating the influence of individual parameters on the incremental costs. ICU Intensive Care Unit, IEEV Ineffective Effort 
Event
Fig. 3 Impact of the price of the analytics on incremental costs
Page 8 of 11Bakker et al. Cost Eff Resour Alloc           (2020) 18:57 
Discussion
We estimated the potential cost-effectiveness of real-time 
analytics that identify ineffective effort events in mechan-
ically ventilated ICU patients. Even when the probability 
that the treatment is effective is low, use of real-time 
analytics could still lead to health benefits for patients 
(0.21 QALYs per person) and savings (€264 per person) 
for healthcare payers. Moreover, there is considerable 
Fig. 4 Cost-effectiveness plane for real-time analytics of an ineffective effort event. Results are presented for three probabilities of a successful 
treatment; 10%, 30% (base case) and 50%
Fig. 5 Cost-effectiveness acceptability curves for real-time analytics of an ineffective effort event. Results are presented for three probabilities of a 
successful treatment; 10%, 30% (base case) and 50%
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headroom for development since the maximum price 
that can be charged per bed varies from €28,994 to 
€140,128 depending on the willingness-to-pay threshold 
used.
This is the first study to examine the cost-effective-
ness of analytics that detect IEEVs. These estimates are 
important to stimulate further development of analyt-
ics that detect IEEVs in real-time since patients with 
IEEVs have much poorer outcomes compared to those 
without IEEVs. Previous studies have emphasized that 
patients with IEEVs have a longer time on mechanical 
ventilation compared to those without IEEVs and authors 
have reported that health and economic benefits can be 
gained by reducing time on mechanical ventilation [25, 
26]. Moreover, Marchuk et  al. found that those patients 
with many ineffective efforts in a brief timeframe had 
reduced oxygen saturation [4]. This further confirms that 
using analytics that enable timely identification of IEEVs 
are essential since this allows clinicians to intervene rap-
idly to improve their oxygen saturation. The underlying 
assumption that an intervention is successful in at least a 
small subset of these patients is an important one in the 
analysis and we cannot be sure that this assumption is 
valid without further research. However, the results avail-
able thus far suggest that it is more likely that an inter-
vention improves outcomes compared to the possibility 
that the intervention has no or a negative effect. First, we 
see that patients with IEEVs are severely worse off com-
pared to patients without IEEVs suggesting that there is 
a lot of room for improvement [4, 5]. Second, IEEVs can 
be identified after 3 min while their median duration at 
present is 21 min leaving a large time window in which a 
clinician can intervene to stop their continuation [5]. This 
is very important because the potential interventions are 
relatively easy to perform, are straightforward and are 
unlikely to lead to any adverse effects. In the unlikely case 
that there would be absolutely no effect of an interven-
tion whatsoever, we expect purchasers would lose money 
but patients would not necessarily be worse off. Since the 
probability of successful treatment influences the health 
benefits and savings from using real-time analytics, we 
recommend further development of these analytics for 
clinical practice and performing a prospective clinical 
trial to assess their true impact. This study should pro-
vide more information about the percentage of patients 
with IEEVs, and the effectiveness of treating them.
Transferability of our findings to other countries and 
hospitals could be influenced by the cost estimates used 
in our analyses. Especially ICU costs had a large influence 
on the results and we therefore varied these costs by 25% 
in the univariate sensitivity analysis. Moreover, we also 
performed a scenario analysis using the ICU costs of the 
Netherlands as an example for other western countries. 
The benefits for hospitals also depend on the reimburse-
ment system in place. Diagnostic related groups in which 
hospitals receive a fixed payment for patients with a spe-
cific diagnosis can stimulate hospitals to reduce length of 
stay which could in turn lead to financial savings for hos-
pitals. However, if services are reimbursed on a fee-for-
service basis in which the hospital is reimbursed for each 
additional day in the hospital, there could be perverse 
incentives to increase length of stay. Either way, the aim 
of healthcare providers should be to maximize the health 
outcomes of their patients which makes use of analytics 
to detect IEEVs desirable. We excluded the possibility 
that alarms generated by the analytics might sometimes 
be ignored because of alert fatigue which could lead to 
lower benefits than estimated here. We also excluded the 
possibility that patients are readmitted to the ICU and 
excluded any side effects of treatments to stop an ineffec-
tive effort event. Even though no patients were readmit-
ted in the observational study and experts thought that 
side effects did not necessarily occur, both should be veri-
fied in a clinical trial.
Our results are not generalizable to all ICU patients 
receiving mechanical ventilation, since we only consid-
ered patients who were expected to remain on propor-
tional assisted mechanical ventilation for a longer period 
of time (> 24 h). Furthermore, a small subset of patients 
can have IEEVs a couple of days after initiation of ven-
tilation support. Our assumption that all treatments are 
performed on the first day could therefore have led to 
an overestimation of the benefits of using the analytics. 
Even though few patients had IEEVs after the first day, 
additional research on the estimated number and timing 
of IEEVs could improve the estimate of the benefits. A 
final limitation is that we did not include any benefits of 
reducing any delays in ICU admission of other patients. 
Since there is a shortage of ICU beds in Greece, reduc-
ing length of stay for patients with IEEVs could reduce 
health losses incurred by other patients because of delays 
in admitting them to the ICU. Therefore, the true benefits 
could be higher than presented here.
Although clinical experts have emphasized the rele-
vance of developing analytics to detect IEEVs [5, 27] their 
adoption is uncertain and compromised by constrained 
budgets and competing investments. Our results pro-
vide developers with estimates of the potential benefits 
of these analytics, which they can show to healthcare 
payers. There is a considerable market that could ben-
efit from analytics that identify IEEVs since the number 
of critical care beds in Europe has been previously esti-
mated at 75,585 [28]. Sixty percent of all ICU patients 
receive mechanical ventilation, of which 30% will receive 
prolonged ventilation [29, 30]. Therefore, the analytics 
would be relevant for 18% of ICU patients. In Greece, 
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there is a shortage of ICU beds and because of this all 
ICU beds are constantly occupied. If this is also the case 
in other European countries, the analytics would be rele-
vant for 18% of these 75,585 beds in Europe alone. Based 
on our results, the analytics should first be assessed in 
countries where ICU costs are high, such as the United 
States or The Netherlands, where the potential financial 
benefits of the analytics would be considerably higher.
Conclusion
Real-time analytics to identify ineffective effort events 
have the potential to improve patient outcomes and gen-
erate financial savings for healthcare payers even when 
the probability of an effective treatment is low. There is 
considerable headroom for development and this should 
therefore be encouraged. Exploitation in countries where 
the costs of an ICU day are high could yield a higher 
return on investment. One important next step is to 
obtain additional clinical evidence of using these analyt-
ics in settings where there is a high frequency of IEEVs.
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